PepTiDa is an academic spin-off from the University of Milan led by Tiziana Borsello that operates in the biotech sector with a focus on neuropharmacology. Its lead program is Simba2, a highly selective inhibitor of the JNK3 enzyme that has shown significant neuroprotective potential in models of cerebral ischemia and Alzheimer’s disease. JNK3 represents both a therapeutic target and a measurable plasma biomarker of pathological brain processes. The company recently received an investment from Mnesys as part of a PNRR-funded initiative to support advanced brain research. No revenue, user, or valuation metrics were disclosed in the article.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2026